• Policy
• Hanmi obtains generic exclusivity for Dapalon Duo
• by Lee, Hye-Kyung Jun 20, 2022 06:03am

• Company
• Hee-Mok Won to “strengthen ties with Korean talents in US"
• by Kim, Jin-Gu Jun 20, 2022 06:03am

• Policy
• BA-linked listed drugs are about to be re-evaluated
• by Lee, Tak-Sun Jun 20, 2022 06:03am

• Company
• Myungin challenges generic for exclusivity of Brintellix
• by Jun 20, 2022 06:03am

• Company
• The α-GPC's sentence of lawsuit has been postponed again
• by Chon, Seung-Hyun Jun 20, 2022 06:03am

• Company
• FDA grants ODD to LG Chem’s oral genetic obesity drug
• by Chon, Seung-Hyun Jun 20, 2022 06:03am

• Policy
• Limited indications of JAKI for high-risk groups
• by Lee, Hye-Kyung Jun 20, 2022 06:02am

• Policy
• The KDCA is pushing for the introduction of Tecovirimat
• by Lee, Jeong-Hwan Jun 20, 2022 06:02am

• Policy
• Limited indications of JAKI for high-risk groups
• by Lee, Hye-Kyung Jun 16, 2022 05:58am

• Policy
• Listing period for new drugs to be reduced up to 60 days
• by Kim, Jung-Ju Jun 16, 2022 05:57am